Gerresheimer sales expand on demand for insulin pens; AmerisourceBergen again snags VA contract; Azerbaijan wants labels in its language;

> Gerresheimer, the German pharmaceutical glass and plastics maker, reports a 14% revenue growth tied to higher sales of insulin pens and syringes. Story

> AmerisourceBergen Corp. ($ABC) and Cardinal Health ($CAH) were unable to wrest away from McKesson Corp. ($MCK) a $4 billion annual contract to supply drugs to Department of Veterans Affairs facilities which McKesson has held for 8 years. Article

> After July 1, Azerbaijan will ban any drugs into the country that do not have annotations in the Azerbaijani language. Story

> Genzyme is adding another 16,000 square feet to a plant in Northborough, MA, for storage of oxidizing gas to support demand since being acquired by Sanofi ($SNY). Story

> Henry Schein, the Melville, NY, supplier to medical, dental and veterinary practices has acquired from AUV Group AUV Veterinary Services, a Dutch company that supplies veterinary practices in Belgium and the Netherlands. Story

> St. Jude Medical's CEO Daniel Starks has embarked on a "scorched earth" defense against reports of deaths and injuries tied to defective leads on its heart defibrillators that may be backfiring. Story

> Lonza, the Swiss contract manufacturer and ingredient supplier, has named Richard Ridinger CEO following the ouster in January of Stefan Borgas after profits took a nosedive. Story

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.